TNF and cancer: Soluble TNF-α receptors from the blood can be removed to boost endogenous TNF-α activity, and this is done using a single chain TNF-α-based affinity column developed by Immunicon Inc. In the experimental cancer model, the efficacy of the agents was improved by a low dose of TNF-α pretreatment.